Sign-up for Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 investment picks
- Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2
- Extends patent coverage to three main markets, U.S., EU and now Japan
PORTLAND, Ore., Oct.
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company
creating innovative personalized therapeutics for patients with
genetically defined cancers, announced today that the US Patent and
Trademark Office has granted Notices of Allowance for US Patent
Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTC Pink: VPLM) is pleased to
announce that the US Patent and Trademark Office (USPTO) has allowed a
seventh patent application “Intercepting Voice Over IP Communications
and Other Data Communications,” Application No.
Hudson Technologies, Inc. (NASDAQ: HDSN), announced that on October 16,
2014 the Environmental Protection Agency (EPA) Administrator Gina
McCarthy signed the final rule pertaining to allowances for virgin
production of HCFCs, primarily R-22, for 2015 through 2019.
Sign-up for Hudson Technologies Reports the EPA’s Issuance of Final Rule on HCFC Allowances for 2015 Through 2019; More Aggressive Final Rule Than the EPA’s Original Preferred Approach investment picks
EXFO Enhances 40G/100G lab testing capabilities to allow NEMs and carrier labs to fully qualify and test 100G network elements Canada NewsWire
Extended multi-stage ODUmuxing and SONET/SDH client mappings now available on the FTB/IQS-85100G Packet Blazer series QUEBEC CITY , Nov.
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today
announced the expansion of its intellectual property portfolio.
Group Inc. (NYSE:CIT), a leading provider of commercial lending and
leasing services, today reported net income of $515 million, $2.76 per
diluted share, for the third quarter of 2014, compared to net income of
$200 million, $0.99 per diluted share, for the year-ago quarter.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.